Benzodiazepine analogs

A compound of Formula II:

• ##STR130## wherein R.sup.1 is H, C.sub.1 -C.sub.6 linear or branched alkyl, loweralkenyl, lower alkynyl, --X.sup.12 COOR.sup.6, --X.sup.11 -cycloloweralkyl, --X.sup.12 NR.sup.4 R.sup.5, --X.sup.12 CONR.sup.4 R.sup.5, --X.sup.12 CN, or --X.sup.11 CX.sub.3.sup.10 ;
• R.sup.2 is H, loweralkyl, substituted or unsubstituted phenyl (wherein the substitutents may be 1 or 2 of halo, loweralkyl, loweralkoxy, loweralkylthio, carboxyl, carboxyloweralkyl, nitro, --CF.sup.3, or hydroxy), 2-, 3-, 4-pyridyl, ##STR131## --X.sup.12 SCH.sub.3, --x.sup.12 SOCH.sub.3, --X.sup.12 SO.sub.2 CH.sub.3, or --X.sup.12 COOR.sup.6 ;
• .sup.3 is ##STR132## with the priviso that R.sup.10 is not H or --CH.sub.3 when R.sup.3 is ##STR133## R.sup.4 and R.sup.5 are independently R.sup.6 or in combination with the N of the NR.sup.4 R.sup.5 group form an unsubstituted or mono or disubstituted, saturated or unsaturated, 4-7 membered heterocyclic ring, or benzofused ,4-7 membered heterocyclic ring wherein said heterocyclic ring or said benzofused heterocyclic ring may contain a second heteroatom selected from O and NCH.sub.3 and the substituent(s) is/are independently selected from C.sub.1 -C.sub.4 alkyl;
• R.sup.6 is H, loweralkyl, cycloloweralkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenylloweralkyl wherein the phenyl or phenylloweralkyl substituents may be 1 or 2 of halo, loweralkyl, loweralkoxy, nitro, or CF.sub.3 ;
• R.sup.7 is .alpha.- or .beta.-naphthyl, substituted or unsubstituted phenyl (wherein the substituents may be independently 1 to 2 of halo, --NO.sub.2, --OH,--X.sup.11 NR.sup.4 R.sup.5, loweralkyl, CF.sub.3, CN, SCF.sub.3, C.tbd.CH, CH.sub.2 SCF.sub.3, ##STR134## OCHF.sub.2, SH, SPh, PO.sub.3 H, loweralkoxy, loweralkylthio or COOH), 2-, 3-, 4- pyridyl, ##STR135## R.sup.8 is H, loweralkyl, cycloloweralkyl, --X.sup.12 CONH.sub.2, --X.sup.12 COOR.sup.6, --X.sup.12 -cycloloweralkyl, --X.sup.12 NR.sup.4 R.sup.5, ##STR136## R.sup.9 and R.sup.10 are independently H, --OH, or --CH.sub.3 ;
• R.sup.11 and R.sup.12 are independently loweralkyl or cycloloweralkyl;
• R.sup.13 is H, loweralkyl, acyl, O, or cycloloweralkyl;
• R.sup.14 is loweralkyl or phenylloweralkyl;
• R.sup.15 is H, loweralkyl, ##STR137## or --NH.sub.2 ;
• R.sup.16 alpha or beta naphthyl or 2-indolyl;
• R.sup.18 is H or loweralkyl;
• p is 0 when its adjacent --- is unsaturated and 1 when its adjacent --- is saturated except that when R.sup.13 is O, p=1 and --- is unsaturated;
• q is 0-4;
• r is 1 or 2;
• X.sup.1 is H, --NO.sub.2, CF.sub.3 CN, OH, loweralkyl, halo, loweralkylthio, loweralkoxy, --X.sup.11 COOR.sup.6, or --X.sup.11 NR.sup.4 R.sup.5,
• X.sup.2 and X.sup.3 are independently H, --OH,--NO.sub.2, halo, loweralkylthio, loweralkyl, or loweralkoxy;
• X.sup.4 is S, O, CH.sub.2, or NR.sup.8 ;
• X.sup.5 is H, CF.sub.3, CN, --COOR.sup.6, NO.sub.2, or halo;
• X.sup.6 is O or HH;
• X.sup.7 is O, S, HH, or NR.sup.15 with the proviso that X.sup.7 can be NR.sup.15 only when R.sup.1 is not H;
• X.sup.8 is H, loweralkyl;
• X.sup.9 and X.sub.a.sup.9 are independently NR.sup.18 or O;
• X.sup.10 is F, Cl, or Br;
• X.sup.11 is absent or C.sub.1-4 linear or branched alkylidene;
• X.sup.12 is C.sub.1-4 linear or branched alkylidene;
• --- is a saturated or unsaturated bond;
• with the proviso that when X.sub.r.sup.1 is Cl in the seven position, R.sup.1 is H and R.sup.2 is unsubstituted phenyl, then R.sup.3 is not NHCO(CH.sub.2).sub.2 C.sub.6 H.sub.5 or NHCOC.sub.6 H.sub.5 or pharmaceutically acceptable salt thereof.